Company Spotlight: iSchemaView Rapid Aortic Measurements - The Shift from Neuro to Aorta

We dive into the FDA 510(k) summary for iSchemaView's Rapid Aortic Measurements, an AI tool designed to evaluate aortic and iliac arteries. We explore its performance data, curious dataset discrepancies, technical limitations, and what this clearance means for health systems looking to automate vascular imaging workflows.

Key points

• Rapid Aortic Measurements (AM) is an AI software that segments and measures the aorta and iliac arteries on CT scans, acting as an aid to physician decision-making.
• The clearance is based on substantial equivalence to the previously cleared Rapid Neuro3D device, indicating a technological shift from brain imaging down to the chest, abdomen, and pelvis.
• Performance testing reported a 100% agreement on segmentation and clinical accuracy by up to 3 clinical experts across a dataset of 108 cases.
• The document contains unexplained dataset discrepancies, such as reporting 108 cases derived from 115 patients, and demographics that do not align perfectly.
• The software has strict exclusion criteria, including series with excessive motion, metal implants, slice thickness greater than 3 mm, and scans from cone-beam CT scanners.

Source: FDA 510(k) summary K251987: Rapid Aortic Measurements (iSchemaView) - U.S. Food and Drug Administration, 2025

This episode is an AI-generated conversation summarising a public document; the hosts' voices are synthetic. It is for information only and is not medical advice. Always refer to the original source.

Company: iSchemaView (ischemaview.com) · Product: Rapid Aortic Measurements · FDA 510(k) K251987

Full transcript: https://ai-in-medicine-podcast.vercel.app/episodes/company-spotlight-ischemaview-rapid-aortic-measurements-the-shift-from-d7896a